Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insider Analysis From L.E.K Consulting On Expanding In China’s Medtech Market (Part 3 of 3)

This article was originally published in PharmAsia News

Executive Summary

Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for multinational device makers.

You may also be interested in...



Insider Analysis From L.E.K Consulting On Expanding in China’s Medtech Market (Part 2 of 3)

Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for multinational device makers.

Insider Analysis From L.E.K Consulting On Expanding In China’s Medtech Market (Part 1 of 3)

Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for device makers wanting to enter China.

Insider Analysis From LEK On Tackling China’s EDL Challenge: Navigating The Changes And Planning For Success

After a review of the newly listed products on China’s Essential Drug List, LEK believes price declines and market access can be managed and continued growth is possible for originator products added to the EDL.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC084657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel